Markus Munder

TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.

TL;DR: Understanding the arginine metabolism of M1/M2 macrophage phenotypes is central to find new possibilities to manipulate immune responses in infection, autoimmune diseases, chronic inflammatory conditions, and cancer.

TL;DR: It is shown that murine bone marrow– derived macrophages (BMMΦ) secrete large amounts of IFN-γ upon appropriate stimulation, and a novel pathway of autocrine macrophage activation is uncovered by demonstrating that themacrophage is not only a key cell type responding to IFN -γ but also a potent IFN–producing cell.

TL;DR: The results suggest that the iNOS/arginase balance in macrophages is competitively regulated in the context of Th1- vs Th2-driven immune reactions, most likely by cytokines without the requirement for direct cell interaction.

TL;DR: Myeloid cell arginase‐mediated L‐arginine depletion profoundly suppresses T cell immune responses and this has emerged as a fundamental mechanism of inflammation‐associated immunosuppression.